These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 37999101)

  • 21. [Association between Immunotherapy with Immune Checkpoint Inhibitors(Anti-PD-1 Antibodies)and Intestinal Microbiota].
    Ozaki Y; Suzuki Y; Nishiyama K; Suzutani T; Suzuki H
    Gan To Kagaku Ryoho; 2021 Sep; 48(9):1096-1099. PubMed ID: 34521783
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of bowel movement condition on immune checkpoint inhibitor efficacy in patients with advanced non-small cell lung cancer.
    Katayama Y; Yamada T; Tanimura K; Yoshimura A; Takeda T; Chihara Y; Tamiya N; Kaneko Y; Uchino J; Takayama K
    Thorac Cancer; 2019 Mar; 10(3):526-532. PubMed ID: 30666802
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of antibiotics on the anti-tumor efficacy of immune checkpoint inhibitor therapy.
    Nie F; Guo J; Pan J; Guo Z; Wang C; Yan J; Ma W
    Clin Transl Oncol; 2024 Jul; ():. PubMed ID: 39046682
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Role of the intestinal microbiome and microbial-derived metabolites in immune checkpoint blockade immunotherapy of cancer.
    Hayase E; Jenq RR
    Genome Med; 2021 Jun; 13(1):107. PubMed ID: 34162429
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Diversity of Gut Microbiome is Associated With Favorable Responses to Anti-Programmed Death 1 Immunotherapy in Chinese Patients With NSCLC.
    Jin Y; Dong H; Xia L; Yang Y; Zhu Y; Shen Y; Zheng H; Yao C; Wang Y; Lu S
    J Thorac Oncol; 2019 Aug; 14(8):1378-1389. PubMed ID: 31026576
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Association of antibiotic exposure with survival in patients with extensive-stage small cell lung cancer receiving immune checkpoint inhibitor therapy.
    Zhong J; Xiong D; Liu Y; Yuan S
    Thorac Cancer; 2024 Jan; 15(2):152-162. PubMed ID: 38010059
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The impact of antibiotic use on clinical features and survival outcomes of cancer patients treated with immune checkpoint inhibitors.
    Zhou J; Huang G; Wong WC; Hu DH; Zhu JW; Li R; Zhou H
    Front Immunol; 2022; 13():968729. PubMed ID: 35967438
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Association of Prior Antibiotic Treatment With Survival and Response to Immune Checkpoint Inhibitor Therapy in Patients With Cancer.
    Pinato DJ; Howlett S; Ottaviani D; Urus H; Patel A; Mineo T; Brock C; Power D; Hatcher O; Falconer A; Ingle M; Brown A; Gujral D; Partridge S; Sarwar N; Gonzalez M; Bendle M; Lewanski C; Newsom-Davis T; Allara E; Bower M
    JAMA Oncol; 2019 Dec; 5(12):1774-1778. PubMed ID: 31513236
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Gut Microbiome and Cancer Immunotherapy: Can We Use the Gut Microbiome as a Predictive Biomarker for Clinical Response in Cancer Immunotherapy?
    Oh B; Boyle F; Pavlakis N; Clarke S; Eade T; Hruby G; Lamoury G; Carroll S; Morgia M; Kneebone A; Stevens M; Liu W; Corless B; Molloy M; Kong B; Libermann T; Rosenthal D; Back M
    Cancers (Basel); 2021 Sep; 13(19):. PubMed ID: 34638308
    [No Abstract]   [Full Text] [Related]  

  • 30. How to Choose a Survival Period? The Impact of Antibiotic Use on OS or PFS in NSCLC Patients Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis.
    Chen H; Han KD; He ZJ; Huang YS
    Technol Cancer Res Treat; 2021; 20():15330338211033498. PubMed ID: 34323149
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The role of the gut microbiome on the efficacy of immune checkpoint inhibitors in Japanese responder patients with advanced non-small cell lung cancer.
    Katayama Y; Yamada T; Shimamoto T; Iwasaku M; Kaneko Y; Uchino J; Takayama K
    Transl Lung Cancer Res; 2019 Dec; 8(6):847-853. PubMed ID: 32010563
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Gut microbiome in modulating immune checkpoint inhibitors.
    Li X; Zhang S; Guo G; Han J; Yu J
    EBioMedicine; 2022 Aug; 82():104163. PubMed ID: 35841869
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies.
    Lu Y; Yuan X; Wang M; He Z; Li H; Wang J; Li Q
    J Hematol Oncol; 2022 Apr; 15(1):47. PubMed ID: 35488243
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Microbiome bacterial influencers of host immunity and response to immunotherapy.
    Yousefi Y; Baines KJ; Maleki Vareki S
    Cell Rep Med; 2024 Apr; 5(4):101487. PubMed ID: 38547865
    [TBL] [Abstract][Full Text] [Related]  

  • 35. ZFHX3 mutation as a protective biomarker for immune checkpoint blockade in non-small cell lung cancer.
    Zhang J; Zhou N; Lin A; Luo P; Chen X; Deng H; Kang S; Guo L; Zhu W; Zhang J
    Cancer Immunol Immunother; 2021 Jan; 70(1):137-151. PubMed ID: 32653938
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The gut microbiota improves the efficacy of immune-checkpoint inhibitor immunotherapy against tumors: From association to cause and effect.
    Xia L; Zhu X; Wang Y; Lu S
    Cancer Lett; 2024 Aug; 598():217123. PubMed ID: 39033797
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Modulation of Gut Microbiota to Enhance Effect of Checkpoint Inhibitor Immunotherapy.
    Wu J; Wang S; Zheng B; Qiu X; Wang H; Chen L
    Front Immunol; 2021; 12():669150. PubMed ID: 34267748
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Relationship between intestinal flora structure and metabolite analysis and immunotherapy efficacy in Chinese NSCLC patients.
    Song P; Yang D; Wang H; Cui X; Si X; Zhang X; Zhang L
    Thorac Cancer; 2020 Jun; 11(6):1621-1632. PubMed ID: 32329229
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The impact of antibiotics on efficacy of immune checkpoint inhibitors in malignancies: A study based on 44 cohorts.
    Wu Q; Liu J; Wu S; Xie X
    Int Immunopharmacol; 2021 Mar; 92():107303. PubMed ID: 33465728
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antibiotic administration shortly before or after immunotherapy initiation is correlated with poor prognosis in solid cancer patients: An up-to-date systematic review and meta-analysis.
    Yang M; Wang Y; Yuan M; Tao M; Kong C; Li H; Tong J; Zhu H; Yan X
    Int Immunopharmacol; 2020 Nov; 88():106876. PubMed ID: 32799113
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.